Abstract
Matchpoint Therapeutics has publicly launched with $70 million in series A financing and an earlier $30 million in seed money to develop covalent drugs for immune diseases. Its founders include Stanford University chemical biologist Nathanael Gray and Harvard Medical School cell biologist Edward Chouchani. Covalent drugs, once considered fringe players , have been gaining traction among drug developers for their ability to form long-lasting bonds with their protein targets. Unlike drugs that form reversible, noncovalent interactions, covalent compounds permanently shut down the disease-linked proteins they bind to, resulting in a potent therapy with a long action time. Selectivity is the name of the game to ensure that the compounds don’t stray to the wrong targets and cause side effects. Matchpoint will initially pursue compounds that latch to cysteines on their protein targets. Cysteine is the most popular covalent docking site among amino acid residues for its strong nucleophilicity and low
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
